Nimorazole

This classification denotes an antiprotozoal agent with the molecular formula C9H14N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 469ULX0H4G, chemically known as morpholine, 4-(2-(5-nitroimidazol-1-yl)ethyl)- but generally known as nimorazole, which bears US NIH Compound Identifier 23009. European Medicines Agency schedules Nimorazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09298MIG. The term NIMORAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules nimorazole in its Anatomical Therapeutic Chemical (ATC) Classification. NIMORAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nimorazole under HS 29349990 and SITC 51579. As of Q4 2014, NIMORAZOLE remains the US FDA Preferred Term for this commodity. Nimorazole bears US NLM identifiers UMLS ID C0028095 and NCI Concept Code C76425. SMILES: O1CCN(CCN2C([N](=O)O)CNC2)CC1.